{
  "drugid": "RxNorm:32937",
  "drugname": "paroxetine",
  "guidelinename": "CYP2D6, CYP2C19 and Selective Serotonin Reuptake Inhibitors",
  "url": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/",
  "guidelinepharmgkbids": [
    "PA166127636",
    "PA166127637",
    "PA166127638",
    "PA166127639"
  ],
  "citations": [
    {
      "pmid": "25974703",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors",
      "authors": [
        "Hicks J Kevin",
        "Bishop Jeffrey R",
        "Sangkuhl Katrin",
        "Müller Daniel J",
        "Ji Yuan",
        "Leckband Susan G",
        "Leeder J Steven",
        "Graham Rebecca L",
        "Chiulli Dana L",
        "LLerena Adrián",
        "Skaar Todd C",
        "Scott Stuart A",
        "Stingl Julia C",
        "Klein Teri E",
        "Caudle Kelly E",
        "Gaedigk Andrea"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2015
    }
  ],
  "recommendations": [
    {
      "implications": {
        "CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2D6": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "0.25"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "0.25"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2D6": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "0.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "0.5"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2D6": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "0.75"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "0.75"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2D6": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "1.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "1.0"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "n/a"
      },
      "drugrecommendation": "No recommendation",
      "classification": "No Recommendation",
      "phenotypes": {
        "CYP2D6": "Indeterminate"
      },
      "activityscore": {
        "CYP2D6": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "n/a"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Greatly reduced metabolism when compared to normal metabolizers. Higher plasma concentrations may increase the probability of side effects."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6 or if paroxetine use warranted, consider a 50% reduction of recommended starting dose and titrate to response.",
      "classification": "Optional",
      "phenotypes": {
        "CYP2D6": "Poor Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "0.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "0.0"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Normal metabolism"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "1.25"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "1.25"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Normal metabolism"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "1.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "1.5"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Normal metabolism"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "1.75"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "1.75"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Normal metabolism"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "2.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "2.0"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Normal metabolism"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "2.25"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "2.25"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "2.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "2.5"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "3.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "3.0"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "3.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "3.5"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "4.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "4.0"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥3.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥3.0"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥3.25"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥3.25"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥3.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥3.5"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥4.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥4.0"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥4.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥4.5"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥5.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥5.0"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2D6": "Increased metabolism to less active compounds when compared to normal metabolizers. Lower/undetectable plasma concentrations may increase probability of pharmacotherapy failure."
      },
      "drugrecommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
      "classification": "Strong",
      "phenotypes": {
        "CYP2D6": "Ultrarapid Metabolizer"
      },
      "activityscore": {
        "CYP2D6": "≥6.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2D6": "≥6.0"
      },
      "comments": "Drug-drug interactions and other patient characteristics (e.g., age, renal function, liver function) should be considered when selecting an alternative therapy.",
      "population": "general",
      "genotypes": null
    }
  ],
  "genes": [
    "CYP2D6"
  ],
  "notesonusage": null,
  "cpicVersion": "v1.22.1",
  "source": "CPIC"
}